EX-99.1 2 tm2617028d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes ──────────────────────────────────────────────────────────────────────── CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical models ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Allo-Evasion™ 5.0 maintains insulin secretion and maintained normoglycemia under allogeneic immune pressure in humanized mouse model without immunosuppression Phase 1 clinical manufacturing process has been established demonstrating consistent endocrine purity and optimal islet cell content CNTY-813 IND submission on track for 4Q 2026; initial clinical data expected in 2H 2027 ─────────────────────────────────────────────────────────────────────────────────────────── PHILADELPHIA, June 8, 2026 - Century Therapeutics, Inc. (‘Centu…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Century Therapeutics, Inc.
IPSCNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events On June 8, 2026, Century Therapeutics, Inc. (the “Company”) issued a press release announcing that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the American Diabetes Association (ADA) 2026 Scientific Sessions (the “Conference”) being held June 5-8th in New Orleans, Louisiana.…
Company context
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of iPSC-derived cell therapies with the potential to meaningfully address autoimmune diseases, including T1D, and cancer. Century's therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.
Current securities
Disclosure sections
Item 8.01Item 8.01 - Other Events
Filed exhibits (2)
EX-99.2 3 tm2617028d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 CNTY-813: Scalable Production of Allo-Evasion 5.0- Engineered iPSC Islets for Off-the-Shelf Cell Therapies Leonardo Velazco-Cruz, PhD 2 • Presenter – Leonardo Velazco-Cruz, PhD • Relevant Financial Relationship – Employee, Century Therapeutics – Stock/Shareholder: Century Therapeutics • Presentation Information: – This presentation describes preclinical research related to CNTY-813, an investigational iPSC-derived islet cell therapy for T1D – The content is intended for scientific and educational discussion – No clinical recommendations will be made Disclosures ───────────────────────────────────────────────────────────────────────────────────────────────────────────────── 3 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements…
Open exhibit ↗